Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis

Zhuang, Z. and Wang, Z. H. and Deng, L. H. and Zheng, Q. and Zheng, G. Q. and Wang, Y.

Front Pharmacol (2019) 10: 1388

DOI: 10.3389/fphar.2019.01388

Abstract

Astragaloside IV (AS-IV), the essential active component of astragalus, possesses diverse biological activities that have beneficial effects against cardiovascular disease. Here, we conducted a preclinical systematic review of 15 studies including 577 animals to establish the efficacy and potential mechanisms of AS-IV for animal models of viral myocarditis (VM). Six databases were searched from inception to October 2018. Application of the Cochrane Collaboration’s tool 10-item checklist and Rev-Man 5.3 software to analyze risk of bias of studies and data on outcome measures revealed study quality scores ranging from 2 to 5. Compared with the control group, AS-IV induced a marked decrease in mortality (P \textless 0.05), inflammation of myocardium and pathological score (P\textless 0.05) and cardiac enzymes expression (P\textless 0.05), and improved the function of the heart (P\textless 0.05). The potential mechanisms of AS-IV action were determined as anti-remodeling of myocardium (n = 1), anti-virus (n = 2), antioxidant (n = 2), anti-inflammatory (n = 6), anti-apoptosis (n = 1) and alleviation of myocardial fibrosis (n = 2). The collective results indicate that AS-IV exerts cardioprotective effects in animals with VM via multiple signaling pathways.

Citation

Zhuang, Z., Wang, Z. H., Deng, L. H., Zheng, Q., Zheng, G. Q., & Wang, Y. (2019). Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis. Front Pharmacol, 10, 1388. https://doi.org/10.3389/fphar.2019.01388 meta-analysis, efficacy, Astragaloside IV, mechanisms, myocarditis

Keywords

• meta-analysis
• efficacy
• Astragaloside IV
• mechanisms
• myocarditis